Financière de Tubize S.A.
TUB
Rang in Aktien
#2223
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
Aktienkurs
$203.04
Marktkapitalisierung
$9.04B
Veränderung (1 Tag)
-7.47%
Veränderung (1 Jahr)
-25.36%
Land
BE
Handel Financière de Tubize S.A. (TUB)
Kategorie
Healthcare
Gewinn für Financière de Tubize S.A. (TUB)
Gewinn im Jun 2026 TTM: $116.73M
Laut den aktuellen Finanzberichten von Financière de Tubize S.A. betragen die aktuellen Gewinne des Unternehmens $116.73M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $97.45M, eine Steigerung gegenüber dem Gewinn im Jahr 2022, der $91.36M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Financière de Tubize S.A. von 2003 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $116.73M | 24.50% |
| 2024 | $93.76M | -3.79% |
| 2023 | $97.45M | 6.66% |
| 2022 | $91.36M | -3.90% |
| 2021 | $95.07M | -70.04% |
| 2020 | $317.28M | -0.32% |
| 2019 | $318.31M | -2.86% |
| 2018 | $327.69M | 2.60% |
| 2017 | $319.38M | 68.35% |
| 2016 | $189.71M | -16.83% |
| 2015 | $228.09M | 209.22% |
| 2014 | $73.76M | -15.46% |
| 2013 | $87.25M | -16.53% |
| 2012 | $104.53M | 15.02% |
| 2011 | $90.88M | 221.98% |
| 2010 | $28.23M | -87.95% |
| 2009 | $234.25M | -15,867.73% |
| 2008 | $-1.49M | -102.49% |
| 2007 | $59.74M | -90.49% |
| 2006 | $628.45M | 78.57% |
| 2005 | $351.93M | 105.84% |
| 2004 | $170.97M | 14.90% |
| 2003 | $148.80M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | 4,418.76% |
US
|
|
| $-3.09B | -2,744.49% |
US
|
|
| $-4.02B | -3,540.48% |
AU
|
|
| $1.95B | 1,571.03% |
NL
|
|
| - | - |
CH
|
